In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

A year after the FDA blessed Roche and Novartis’ Xolair (omalizumab) as the first medicine to reduce allergic reactions that can occur from accidental exposure to certain foods, the companies have ...

Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV ...

More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an ...

Treating babies with antibiotics produce short-term microbiome changes that raise their risk for childhood asthma.

Novartis is cueing up a new indication in the ... Kidney Week congress in San Diego over the weekend – showed that Fabhalta (iptacopan) was able to achieve a sustained and significant reduction ...

Michael Harris II led off the fifth with a home run and added a three-run shot later in the frame to highlight a nine-run ...

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis ...

Omalizumab is superior to oral immunotherapy (OIT) for multifood allergy, and most patients include dietary consumptio ...

Novartis is now responsible for worldwide development ... director of vascular medicine at the University of California San Diego (UCSD) – a drug that reduces Lp(a) could be “a paradigm ...

More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an ...